Second monotherapy in childhood absence epilepsy.

Area of Science:

• Pediatric Neurology
• Epileptology
• Clinical Pharmacology

Background:

• Childhood absence epilepsy (CAE) often requires multiple treatment strategies.
• Initial monotherapy failure necessitates evaluation of second-line treatments.

Purpose of the Study:

• To identify the optimal second monotherapy for pediatric patients with CAE who did not respond to initial treatment.
• To compare the efficacy and tolerability of ethosuximide, valproic acid, and lamotrigine as second-line treatments.

Main Methods:

• A randomized controlled trial involving 208 children with CAE.
• Participants received open-label second monotherapy with ethosuximide, valproic acid, or lamotrigine.
• Primary outcome: freedom from seizure failure at 16-20 weeks and 12 months. Secondary outcome: attentional dysfunction.

Main Results:

• Ethosuximide and valproic acid showed similar and superior freedom from failure rates compared to lamotrigine.
• Seizure control was significantly better with ethosuximide and valproic acid versus lamotrigine.
• Attentional dysfunction was more frequent with valproic acid than with ethosuximide or lamotrigine.

Conclusions:

• Ethosuximide and valproic acid are more effective second monotherapies than lamotrigine for CAE.
• Valproic acid is associated with a higher incidence of attentional dysfunction.
• Ethosuximide is identified as the optimal second monotherapy for children with CAE refractory to initial treatments.